Whooping cough, a bacterial infection that can be especially dangerous for babies and young children, is on the rise. As of ...

Most US teens have received a dose of the meningococcal vaccine, yet uptake of the first dose and completion of the booster ...

A joint procurement contract between the EU and Danish manufacturer Bavarian Nordic strengthens vaccine preparedness against ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed ...

Real-world effectiveness with the recommended single dose of respiratory syncytial virus (RSV) vaccination dipped in older ...

Researchers at University of Tsukuba have demonstrated that during Japan's COVID-19 booster vaccination campaign, online information influenced vaccination intentions in ways similar to the initial ...

Valneva's Phase 2 data show strong, lasting immunity for its Pfizer-partnered Lyme vaccine as the company consolidates operations in France.

Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

The effectiveness of a single respiratory syncytial virus (RSV) vaccine dose declined among older adults, potentially suggesting the need for booster shots among this demographic. That is according to ...

Today’s announcement is a powerful example of what our Vaccine Alliance does best,” said An Vermeersch, Gavi’s Chief Vaccine ...

Investing.com -- Valneva SE stock rises after the company reported final positive Phase II data for its Lyme disease vaccine candidate VLA15, showing strong immune responses following a third annual ...